Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations
- PMID: 10469327
- DOI: 10.1046/j.1523-1747.1999.00709.x
Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations
Abstract
Non-sense mutations on both alleles of either the type VII collagen gene (COL7A1) or the genes encoding laminin 5 (LAMA3, LAMB3, or LAMC2) usually result in clinically severe forms of recessive dystrophic or junctional epidermolysis bullosa, respectively. In this study we assessed two unrelated families whose mutations in genomic DNA predicted severe recessive dystrophic epidermolysis bullosa or junctional epidermolysis bullosa phenotypes but in whom the manifestations were milder than expected. The recessive dystrophic epidermolysis bullosa patients had a homozygous single base-pair frameshift mutation in exon 19 of COL7A1 (2470insG). Clinically, there was generalized blistering but only mild scarring. Skin biopsy revealed positive type VII collagen immunoreactivity and recognizable anchoring fibrils. The junctional epidermolysis bullosa patients were compound heterozygotes for a frameshift/non-sense combination of mutations in exons 3 and 17 of LAMB3 (29insC/Q834X). These patients did not have the lethal form of junctional epidermolysis bullosa but, as adults, displayed the milder generalized atrophic benign epidermolysis bullosa variant. There was undetectable laminin 5 staining at the dermal-epidermal junction using an antibody to the beta3 chain, but faintly positive alpha3 and gamma2 chain labeling, and there was variable hypoplasia of hemidesmosomes. To explain the milder recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa phenotypes in these families, reverse transcription-polymerase chain reaction, using RNA extracted from frozen skin, was able to provide evidence for some rescue of mutant mRNA transcripts with restoration of the open- reading frame. In the recessive dystrophic epidermolysis bullosa patients, transcripts containing in-frame skipping of exon 19 of COL7A1 in the cDNA were detected, and in the junctional epidermolysis bullosa patients transcripts with in-frame skipping of exon 17 of LAMB3 were identified. The truncated proteins encoded by these transcripts are expected to lack certain critical domains involved in cell-matrix attachment, but may still be able to contribute to adhesion thereby moderating the severity of the skin blistering. This study shows the limitations in predicting phenotype in epidermolysis bullosa solely based on mutation analysis of genomic DNA and emphasizes the importance of immunohistochemistry, electron microscopy, and mRNA assessment as parallel investigations.
Similar articles
-
Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa.J Invest Dermatol. 1998 Nov;111(5):744-50. doi: 10.1046/j.1523-1747.1998.00397.x. J Invest Dermatol. 1998. PMID: 9804332
-
A recurrent frameshift mutation in exon 19 of the type VII collagen gene (COL7A1) in Mexican patients with recessive dystrophic epidermolysis bullosa.Exp Dermatol. 1999 Feb;8(1):22-9. doi: 10.1111/j.1600-0625.1999.tb00344.x. Exp Dermatol. 1999. PMID: 10206718
-
Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes.J Invest Dermatol. 1994 Nov;103(5 Suppl):39S-46S. doi: 10.1111/1523-1747.ep12398967. J Invest Dermatol. 1994. PMID: 7963683 Review.
-
Mutation analysis and molecular genetics of epidermolysis bullosa.Matrix Biol. 1999 Feb;18(1):29-42. doi: 10.1016/s0945-053x(98)00005-5. Matrix Biol. 1999. PMID: 10367729 Review.
-
Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa.J Invest Dermatol. 1996 Aug;107(2):171-7. doi: 10.1111/1523-1747.ep12329570. J Invest Dermatol. 1996. PMID: 8757758
Cited by
-
Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.Int J Mol Sci. 2021 Mar 24;22(7):3326. doi: 10.3390/ijms22073326. Int J Mol Sci. 2021. PMID: 33805154 Free PMC article.
-
Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.J Med Genet. 2007 Mar;44(3):181-92. doi: 10.1136/jmg.2006.045302. Epub 2006 Sep 13. J Med Genet. 2007. PMID: 16971478 Free PMC article.
-
Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1.Int J Mol Sci. 2020 Oct 18;21(20):7705. doi: 10.3390/ijms21207705. Int J Mol Sci. 2020. PMID: 33081018 Free PMC article.
-
Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.Mol Ther. 2016 Aug;24(7):1302-11. doi: 10.1038/mt.2016.92. Epub 2016 May 9. Mol Ther. 2016. PMID: 27157667 Free PMC article.
-
Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.Hum Genet. 2005 Jan;116(1-2):33-42. doi: 10.1007/s00439-004-1210-y. Epub 2004 Nov 5. Hum Genet. 2005. PMID: 15538630
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources